[Partnership and cancer: do cancer patients and their partners experience changes in their relationship affected by the disease - can a secondary or tertiary gain of illness be observed?].

This work is to study the changes in the partnership during cancer and identify a possible secondary or tertiary disease profit. Thirty-two patients and their partners (n = 64) participated. 84% of patients experience a change in the partner relationship in a positive direction.

Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.

Background: LNCaP and its derivative cell lines, which include C4-2 (and the related C4-2B) and CL1, are used as models of prostate cancer. Unlike LNCaP, the other cell lines show features of progressed disease such as metastatic capability and hormone independence. Analyses were done to determine if C4-2 or CL1 cells were selected from pre-existent subpopulations in LNCaP.